| Autor: |
Akin Osibogun, Akin Abayomi, Oluchi Kanma-Okafor, Jide Idris, Abimbola Bowale, Ololade Wright, Bisola Adebayo, Segun Ogboye, Remi Adeseun, Ismael Abdus-Salam, Bamidele Mutiu, Babatunde Saka, Dayo Lajide, Sam Yenyi, Rotimi Agbolagorite, Oluwatosin Onasanya, Eniola Erinosho, Joshua Obasanya, Olu Adejumo, Sunday Adesola, Yewande Oshodi, IorhenE Akase, Shina Ogunbiyi, Adenike Omosun, Femi Erinoso, Hussein Abdur-Razzaq, Nike Osa, Kingsley Akinroye |
| Rok vydání: |
2020 |
| Popis: |
Background: The current pandemic of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown epidemiological and clinical characteristics that appear worsened in hypertensive patients with COVID-19. The morbidity and mortality of the disease among hypertensive patients in Africa have yet to be well described.Methods: In this retrospective cohort study all confirmed COVID-19 adult patients (≥18 years of age) in Lagos between February 27 to July 6 2020 were included. Demographic, clinical and outcome data were extracted from electronic medical records of patients admitted at the COVID-19 isolation centers in Lagos. Outcomes included dying or being discharged by July 6, 2020. Variables were compared between hypertensive and non-hypertensives using univariable and multivariable logistic regression, cox regression and Kaplan Meier survival analysis methods to assess hypertension as a risk factor associated with worsened disease severity and death.Results: A total of 2075 adults with COVID-19 were included in this study. The prevalence of hypertension was 17.8% and it was the most common comorbidity followed by diabetes (7.2%) and asthma (2.0%). Overall mortality from COVID-19 was 4.2% while mortality among the hypertensives was 13.7%. Severe symptoms and mortality were significantly higher among the hypertensives and survival rates were significantly lowered by the presence of an additional comorbidity to 50% from 91% for those with hypertension alone and from 98% for all other patients (PConclusion: The potential morbidity and mortality risks of hypertension especially with other comorbidities in COVID-19 could help direct efforts towards prevention and prognostication. This provides the rationale for improving preventive caution for people with hypertension and other comorbidities and prioritizing them for future antiviral interventions. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
